nsc-87877 has been researched along with Myasthenia Gravis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beeson, D; Cao, M; Cossins, J; De Rosa, A; Evoli, A; Huda, S; Maestri, M; Ricciardi, R; Rodriguez Cruz, PM; Vincent, A; Woodhall, M | 1 |
1 other study(ies) available for nsc-87877 and Myasthenia Gravis
| Article | Year |
|---|---|
SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody.
Topics: Enzyme Inhibitors; Humans; In Vitro Techniques; Muscle Fibers, Skeletal; Myasthenia Gravis; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Cholinergic | 2020 |